List view / Grid view
Biomarkers are a naturally occurring molecule, gene, or characteristic by which a particular disease can be identified.
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
Men and women heal bone injuries through distinct biological processes, challenging assumptions in regenerative medicine. The findings support the development of personalised implants and more effective, sex-specific treatment strategies.
Deep learning is transforming lung disease treatment by enabling earlier diagnosis, precise monitoring and more efficient clinical trials. This article explores how AI-driven imaging is accelerating drug development and improving patient outcomes.
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
Dr Shika Pappoe’s journey from Yale and Harvard to transforming kidney care highlights how combining clinical expertise with innovation can reshape healthcare. Read on for her insights on overcoming challenges and driving change in STEM and patient care.
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
A new discovery from the University of Geneva highlights the crucial role of the CH25H enzyme, which is found in cancerous lymphatic cells. This enzyme plays a key part in activating immune cells, opening up a promising pathway for improving the success of cancer immunotherapies.
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
29 January 2025 | By Eurofins Discovery
Explore how a Weight of Evidence (WoE) approach uses in vitro methods and artificial intelligence (AI) to transform carcinogenicity risk assessment, reducing reliance on animal studies while enhancing compliance with FDA and ICH guidelines.
Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson's disease (PD).
